AbbVie price to free cash flow ABBV

Market value divided by free cash flow over the last twelve months, since 2014.

Today, Oct 23, 2026: 27.7×
10-year median: 12.4×
Against its 10-year history: 100th; percentile: 0 is its lowest day, 100 its highest
10-year range: 7.3× to 27.7×
Peer median: 18.9×

AbbVie's price to free cash flow is 27.7× as of Oct 23, 2026.

That is above its ten-year median of 12.4×, higher than on 100% of days in the last ten years.

Over that time it ranged from 7.3× in Aug 2019 to 27.7× in Oct 2026.

The median for 7 large drugmakers of a similar size is 18.9×.

Price to free cash flow over time

median 12.4×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	27.7×	17.8×	27.7×
2025	20.6×	17.1×	22.7×
2024	20.1×	11.6×	22.6×
2023	11.1×	9.9×	13.4×
2022	13.0×	10.7×	14.1×
2021	11.0×	9.5×	12.8×
2020	12.3×	8.0×	12.4×
2019	10.2×	7.3×	11.3×
2018	11.5×	10.7×	23.3×
2017	18.3×	14.0×	23.0×
2016	14.6×	11.9×	21.6×
2015	21.7×	19.0×	35.9×
2014	22.4×	12.8×	23.3×

Against its peers

Companies in Drug Manufacturers - General nearest AbbVie's size, closest first, today.

Company	Price to free cash flow
ABBVAbbVie	27.7×
JNJJohnson & Johnson	n/m
MRKMerck	22.3×
AMGNAmgen	23.3×
LLYEli Lilly and	65.9×
GILDGilead Sciences	14.9×
PFEPfizer	15.6×
BMYBristol-Myers Squibb	11.0×
Peer median	18.9×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on AbbVie

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.